[BT Financial Report Instant Analysis] Baolingbao Biology Q1 2024 Report: Significant net income growth, evident cash flow pressure.
As the leading company in the domestic functional sugar industry, Baolingbao (stock code: 002286) recently released its financial report for the first quarter of 2024. Through an in-depth analysis of this financial report data, we can gain insights into the company's operation and possible future development trends. First, looking at the asset and liability data, Baolingbao's total assets at the end of the period amounted to 2.654 billion yuan, a slight decrease compared to the beginning of the period, with a decrease of about 0.20%. The total liability balance at the end of the period has increased to 0.698 billion yuan, with an increase of about 3.32%, leading to an increase in the asset-liability ratio from 25.4% at the beginning of the period to 26.3%.
Bowling Bao (002286.SZ): As of May 10, 2024, the total number of shareholders of the company was 38,748
Gelonghui, May 16, 丨 Bowling Bao (002286.SZ) said on the investor interactive platform that as of May 10, 2024, the total number of shareholders of the company was 38,748.
Bowling Bao (002286.SZ): The production process will use synthetic biotechnology to improve product conversion rate and energy utilization
Gelonghui, May 7 | Bowling Bao (002286.SZ) said on the investor interactive platform that the company's main business is the manufacture of functional sugar products, and the company's production process will use synthetic biotechnology to improve product conversion rate and energy utilization rate.
Weak Statutory Earnings May Not Tell The Whole Story For Baolingbao BiologyLtd (SZSE:002286)
The subdued market reaction suggests that Baolingbao Biology Co.,Ltd.'s (SZSE:002286) recent earnings didn't contain any surprises. Our analysis suggests that along with soft profit numbers, investor
Bowling Bao (002286.SZ): Net profit of 23.1682 million yuan in the first quarter increased 35.89% year-on-year
On April 29, Ge Longhui (002286.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 551 million yuan, down 9.68% year on year; net profit attributable to shareholders of listed companies was 23.1682 million yuan, up 35.89% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 20.33.96 million yuan, up 59.01% year on year; basic earnings per share were 0.06 yuan.
Bowling Bao (002286.SZ): We have deep partnerships with many beverage and food brands such as Wahaha
Gelonghui, March 8, 丨 Bowling Bao (002286.SZ) said on the investor interactive platform that the company's products are widely used in the food and beverage field, have deep cooperative relationships with many brands of beverages and food companies such as Wahaha, and that specific cooperation information with customers has confidentiality clauses that are difficult to disclose.
Just Three Days Till Baolingbao Biology Co.,Ltd. (SZSE:002286) Will Be Trading Ex-Dividend
Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be intrigued to know that Baolingbao Biology Co.,Ltd. (SZSE:002286) is about to go ex-
Bowling Bao (002286.SZ) plans to pay 0.8 yuan for 10 shares to be deducted from interest on March 8
Bowling Bao (002286.SZ) announced that the company's 2023 equity distribution plan: 0.8 yuan for every 10 shares...
Bowling Bao (002286.SZ): As of February 8, 2024, the total number of shareholders of the company was 35,704
On February 21, Ge Longhui (002286.SZ) said on the investor interactive platform that as of February 8, 2024, the total number of shareholders of the company was 35,704.
Pinning Down Baolingbao Biology Co.,Ltd.'s (SZSE:002286) P/E Is Difficult Right Now
With a price-to-earnings (or "P/E") ratio of 34.7x Baolingbao Biology Co.,Ltd. (SZSE:002286) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E rat
Bowling Bao (002286.SZ): 2023 net profit pre-reduced by 57.95%-60.95%
On January 26, Ge Longhui (002286.SZ) announced its 2023 annual results forecast. Net profit attributable to shareholders of listed companies during the reporting period was 52 million yuan to 56 million yuan, down 57.95%-60.95% from the same period last year; net profit profit after deducting non-recurring profit and loss was 33 million yuan to 37 million yuan, down 70.18% to 73.40% over the same period last year; basic earnings per share were 0.1,402 yuan/share — 0.1510 yuan/share. The main reason for the change in performance was the temporary decline in market demand and competition from the same industry for erythritol
Huaan Securities: The new functional sugar substitute market is expected to bring investment opportunities in the industrial chain from 0-1
The process of the new functional sugar substitute market from 0-1 is expected to bring investment opportunities in the industrial chain.
Bowling Bao (002286.SZ) once again passed the high-tech enterprise certification
Gelonghui (002286.SZ) announced on December 19|Baolingbao (002286.SZ) announced. Recently, according to the “Notice on Filing the First Batch of High-tech Enterprises Registered by Shandong Accreditation Authority in 2023" issued by the Office of the National High-tech Enterprise Accreditation Management Leading Group, we learned that the company was included in the first batch of high-tech enterprises registered by the Shandong Provincial Certification Authority in 2023, and the company once again successfully passed the high-tech enterprise certification.
Bowling Bao (002286.SZ): The approval of the non-public stock offering in 2021 expires and expires and the relevant termination agreement is signed
Gelonghui (002286.SZ) announced on November 17|Bowlingbao (002286.SZ) announced that due to changes in the internal and external objective environment and market environment, the erythritol project of the company's proposed fund-raising project has been completed with the company's own capital. Affected by changes in market conditions, the company has adjusted the production capacity of erythritol and transferred part of the production capacity to other high-margin products; taking into account changes in the market environment, reducing investment risks, and improving the efficiency of the use of existing assets, etc., the implementation method of the “annual production of 30,000 tons of alloketone sugar (dry base) project” has also been adjusted. transformation, Reduce the amount of additional investment and collect
Bowling Bao (002286.SZ): Epomycin was an early cooperative project between the company and a third party, and no industrialization has yet been achieved
Gelonghui November 15 | Bowling Bao (002286.SZ) said on the investor interactive platform that the company focuses on the R&D, production and sales of functional sugar products. At this stage, the company has expanded the application of erythritol and maltodextrin products with pharmaceutical excipient qualifications in the pharmaceutical field. Epomycin is an early cooperative project between the company and a third party, but has not yet been industrialized.
Bowling Bao (002286.SZ): Does not contain non-sugar sweeteners such as aspartame
Glonghui, October 31, Bowling Bao (002286.SZ) stated on the investor interactive platform that the company's main products are natural healthy sugar substitute products such as oligosaccharides, fructose syrup, erythritol, crystalline fructose, alloketose, resistant dextrin, and polyglucose, and do not contain non-sugar sweeteners such as aspartame.
Bowling Bao (002286.SZ): Some research reports show that taking D-aloxone can promote the release of GLP-1
Glonghui, October 31, Bowling Bao (002286.SZ) said on the investor interactive platform that some research reports showed that taking D-alloketone can promote the release of GLP-1 (glucose-like peptide-1) and wander into the nerves through GLP-1 receptor signals, which have the effect of suppressing food intake and hyperglycemia, and the effects are related to the time of intake, which is still in the research stage.
Bowling Bao (002286.SZ): Net profit for the first three quarters was 459.888 million yuan, down 58.41% year on year
On October 27, Gelonghui (002286.SZ) announced its third quarter report. Operating income was 1,965 billion yuan, down 5.56% year on year, net profit was 459.88 million yuan, down 58.41% year on year, net profit was 45.98 million yuan, down 58.41% year on year, deducting non-net profit of 30.2576 million yuan, down 70.35% year on year, and basic earnings per share of 0.12 yuan.
Earnings Are Growing at Baolingbao BiologyLtd (SZSE:002286) but Shareholders Still Don't Like Its Prospects
For many investors, the main point of stock picking is to generate higher returns than the overall market. But its virtually certain that sometimes you will buy stocks that fall short of the market a
Bowling Baby (002286.SZ): Alloxose has a history of only 3 to 5 years in China, and there is a certain difference in technical maturity
Glonghui, Oct. 17 | Bowling Bao (002286.SZ) said in an interview with a specific subject on October 12 that the only difference is that erythritol has been industrialized for about 10 years, while alloxose has only a history of 3 to 5 years in China, so there is a certain difference in technical maturity.
No Data